Compositions And Methods Of Use Of Phorbol Esters
AssigneeBiosuccess Biotech Co. Ltd.
InventorsZheng Tao Han, Hung-Fong Chen
Life of this patent
Estimating the term…
Abstract
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
Claims194
1-48. (canceled)
A method of treating or preventing neoplasms in a mammalian subject comprising administering an effective amount of a phorbol ester or derivative of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is selected from hydrogen,
- and substituted derivatives thereof;
- and at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester or derivative compound of Formula I to treat or prevent neoplasms in said subject.
A method for preventing or treating one or more symptoms or conditions of neoplastic disease in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof;
- and at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester or derivative compound of Formula to treat or prevent symptoms of neoplastic disease in said subject.
A method for inducing remission in a mammalian subject suffering from neoplastic disease comprising administering to said subject an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof, to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof;
- R3 is hydrogen,
- and substituted derivatives thereof;
- and at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of derivative compound of Formula I to induce remission in said subject.
A method for inducing apoptosis in a neoplasm in a mammalian subject suffering from neoplastic disease comprising administering to said subject an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof, to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof;
- and at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation Or coordinate treatment regimen with said phorbol ester of derivative compound of Formula I to induce apoptosis in a neoplasm in said subject.
A composition for preventing or treating neoplastic disease in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof;
- and at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation with said phorbol ester or derivative compound of Formula I to treat or prevent a neoplasm in said subject.
A method for preventing or treating one or more side effects of chemotherapy in a mammalian subject comprising administering an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for preventing or treating one or more side effects of chemotherapy in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for preventing or treating one or more side effects of radiation therapy in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for preventing or treating one or more side effects of radiation therapy in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for preventing or treating one or more of the effects of stroke in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of one or more effects of stroke in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing one or more of the symptoms of Parkinson's disease in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of one or more symptoms of Parkinson's disease in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing one or more of the symptoms of prostate hypertrophy in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of one or more symptoms of prostate hypertrophy in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing one or more of the symptoms of rheumatoid arthritis in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of one or more symptoms of rheumatoid arthritis in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing one or more of the symptoms of myasthenia gravis in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of one or more symptoms of myasthenia gravis in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing symptoms of kidney disease in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of kidney disease in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A method for treating or preventing urinary incontinence in a mammalian subject comprising administering an effective amount of phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof to said subject
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
A composition for the prevention or treatment of urinary incontinence in a mammalian subject comprising an effective amount of a phorbol ester or derivative compound of Formula I, or a pharmaceutically-acceptable salt, isomer, enantiomer, solvate, hydrate, polymorph or prodrug thereof
- wherein R1 and R2 are selected from the group consisting of hydrogen,
- and substituted derivatives thereof, R3 is hydrogen,
- and substituted derivatives thereof.
Dependencies are inferred from the claim text.